You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Relationship between disease-free survival with clinico-pathological factors

From: Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer

Variable N= 112 1-year DFS (months ± SD) 2-year DFS (months ± SD) 5-year DFS (months ± SD) Univariate analysis p Multivariate analysis HR (95% CI) p
Age (years)     0.09  
   >50 92 ± 3 82 ± 5 82 ± 5   
   <50 96 ± 2 94 ± 2 92 ± 3   
Clinical T stage*     0.05  
   T2 90 ± 6 86 ± 7 86 ± 7   
   T3 98 ± 2 96 ± 2 96 ± 2   
   T4 87 ± 5 82 ± 6 78 ± 6   
Clinical N stage*     0.79  
   N1 92 ± 3 90 ± 4 90 ± 4   
   N2/N3 92 ± 3 87 ± 4 84 ± 5   
Clinical stage*     0.03 3.1 (1.02–9.74,) 0.0406
   IIB/IIIA 95 ± 2 93 ± 3 93 ± 3   
   IIIB 87 ± 5 82 ± 6 78 ± 6   
Estrogen receptors     0.012 0.3 (0.91–1.22,) 0.97
   Negative 92 ± 3 85 ± 4 83 ± 4   
   Positive 97 ± 2 93 ± 3 93 ± 3   
Histological grade†     0.04 3.5 (0.79–16.28,) 0.98
   Low/moderate 100 97 ± 2 94 ± 3   
   High 91 ± 3 83 ± 4 83 ± 4   
Pathological response     0.56  
   pCR/microscopic 92 ± 3 88 ± 3 86 ± 4   
   Residual 94 ± 4 91 ± 4 91 ± 4   
  1. Abbreviations: DFS = disease-free survival; SD = standard deviation; HR = Hazard ratio; 95% CI = 95% confidence interval.
  2. * 6th edition of the American Joint Committee on Cancer TNM classification and staging system.
  3. † Scarff-Bloom-Richardson (SBR) scale.